Investment solutions based on popular smart beta indices have enjoyed tremendous success. These generic products, however, raise serious issues regarding their ability to efficiently harvest factor premiums.
This study1 by MSCI examined how their popular Minimum Volatility (MV) index could be modified in order to address various concerns. The authors show that concentration, sustainability, and valuation concerns can be mitigated by using appropriate but simple optimization constraints.
These results are consistent with our own experience with low volatility strategies. However, we wonder how many passive investors will be able to benefit from these insights, as long as these are not incorporated into the standard MSCI MV index, which is likely to remain the preferred choice for most investors.
The study also found that adding a ‘maximum diversification’ (MD) constraint to the MV index leads to a clear deterioration in performance, which is interesting given the popularity of MD strategies. The study showed that MD tilts the portfolio towards stocks with high stock-specific risks, and that this hurts performance, given the poor long-term performance characteristics of such stocks.
1 Alighanbari, Doole & Melas, ‘Managing Risks Beyond Volatility’, Journal of Index Investing, Vol. 8, No. 2, 2017, pp. 68-76.
The information contained on these pages is for marketing purposes and solely intended for Qualified Investors in accordance with the Swiss Collective Investment Schemes Act of 23 June 2006 (“CISA”) domiciled in Switzerland, Professional Clients in accordance with Annex II of the Markets in Financial Instruments Directive II (“MiFID II”) domiciled in the European Union und European Economic Area with a license to distribute / promote financial instruments in such capacity or herewith requesting respective information on products and services in their capacity as Professional Clients.
The Funds are domiciled in Luxembourg and The Netherlands. ACOLIN Fund Services AG, postal address: Affolternstrasse 56, 8050 Zürich, acts as the Swiss representative of the Fund(s). UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zurich, postal address: Europastrasse 2, P.O. Box, CH-8152 Opfikon, acts as the Swiss paying agent. The prospectus, the Key Investor Information Documents (KIIDs), the articles of association, the annual and semi-annual reports of the Fund(s) may be obtained, on simple request and free of charge, at the office of the Swiss representative ACOLIN Fund Services AG. The prospectuses are also available via the website www.robeco.ch. Some funds about which information is shown on these pages may fall outside the scope of the Swiss Collective Investment Schemes Act of 26 June 2006 (“CISA”) and therefore do not (need to) have a license from or registration with the Swiss Financial Market Supervisory Authority (FINMA).
Some funds about which information is shown on this website may not be available in your domicile country. Please check the registration status in your respective domicile country. To view the RobecoSwitzerland Ltd. products that are registered/available in your country, please go to the respective Fund Selector, which can be found on this website and select your country of domicile.
Neither information nor any opinion expressed on this website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco Switzerland Ltd. product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports.